OBJECTIVES
Pharmaceuticals can be used in un-approved or unlicensed indications or dosages apart from their licensed use. This is called off-label use. In principle, a drug can be considered to be off label under three conditions: (i) if the approval have not been extended, although evidence of efficacy is available; (ii) if it falls into the so-called 'grey zone' of evidence-based medicine, within which high-level evidence is difficult to reach even for treatments which are likely to be effective and (iii) if the drug is ineffective or at least there is no reason to believe it is effective (Koçkaya et al., 2011) .
Off-label use is defined by the Turkish Ministry of Health (MoH) as the use of licensed pharmaceutical products in doses outside of or exceeding the scope of the registered indication and the use of unlicensed medicinal products that are imported for the purpose of individual treatment. Hence, off-label use covers both licensed and unlicensed products (Koçkaya et al., 2012) . 
METHODS
This study was designed as an observational, retrospective study. Consumption data of the top 100 imported unlicensed medicines with the highest sales share in total expenses of imported off-label use was taken from the TMMDA database.
Descriptive analysis was conducted. Active ingredients of medicines were sorted based on ATC classification. Total units sold of top 100 and average cost per unit of top 100 were also calculated. 
RESULTS CONCLUSIONS

